ProbeChem®
Expedite Your Scientific Research

WWW.PROBECHEM.COM

# Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

| | | |
|---|---|---|
| **Product Name** | : | Atractylenolide I |
| **Cat. No.** | : | PC-27935 |
| **CAS No.** | : | 73069-13-3 |
| **Molecular Formula** | : | $C_{15}H_{18}O_2$ |
| **Molecular Weight** | : | 230.31 |
| **Target** | : | Proteasome |
| **Solubility** | : | 10 mM in DMSO |



## Biological Activity

Atractylenolide I (ATT-I, AT-I) is a sesquiterpene derived from the rhizome of Atractylodes macrocephala within neuroprotective, anti-allergic, anti-inflammatory and anticancer properties, targets and binds proteasome 26S subunit non-ATPase 4 (PSMD4) with MST KD of 0.4 uM, enhances antigen presentation on tumor cells.
Atractylenolide I (ATT-I) promotes CD8+ T cell–mediated tumor cell killing.
Atractylenolide I (ATT-I) enhances the antigen-specific T cell responses in MC38 tumor–derived organoids.
Atractylenolide I (ATT-I) promotes the activity of immunoproteasome in a PSMD4-dependent manner, binds to PSMD4 and stabilizes the PSMD4 and PSMD7 interaction, leading to enhanced proteasomal activities.
Atractylenolide I (ATT-I) promotes antigen presentation and enhances the efficacy of CRC immunotherapy.
Atractylenolide I (ATT-I) enhances tumor-infiltrating lymphocytes and antitumor activity of cytotoxic T lymphocytes.

## References

Xu H, et al. J Clin Invest. 2026 May 1;136(9):e208647.

Miao Y, et al. iScience. 2026 Aug 21;29(9):117259.



E-mail: tech@probechem.com